Edition:
United Kingdom

Astellas Pharma Inc (4503.T)

4503.T on Tokyo Stock Exchange

1,707JPY
20 Feb 2019
Change (% chg)

¥18 (+1.07%)
Prev Close
¥1,689
Open
¥1,700
Day's High
¥1,712
Day's Low
¥1,696
Volume
6,720,600
Avg. Vol
6,714,581
52-wk High
¥2,056
52-wk Low
¥1,356

Latest Key Developments (Source: Significant Developments)

Astellas Pharma To Buy Back Up To 40 Million Shares Worth 60 Billion Yen Through March 20
Thursday, 31 Jan 2019 

Jan 31 (Reuters) - Astellas Pharma Inc <4503.T>::TO BUY BACK UP TO 40 MILLION SHARES WORTH 60 BILLION YEN THROUGH MARCH 20.  Full Article

Astellas And Pfizer Announce Positive Top-Line Results From Phase 3 Arches Trial Of Xtandi
Thursday, 20 Dec 2018 

Dec 20 (Reuters) - Pfizer Inc ::ASTELLAS AND PFIZER ANNOUNCE POSITIVE TOP-LINE RESULTS FROM PHASE 3 ARCHES TRIAL OF XTANDI® (ENZALUTAMIDE) IN MEN WITH METASTATIC HORMONE-SENSITIVE PROSTATE CANCER.ASTELLAS AND PFIZER ANNOUNCE POSITIVE TOP-LINE RESULTS FROM PHASE 3 ARCHES TRIAL OF XTANDI® (ENZALUTAMIDE) IN MEN WITH METASTATIC HORMONE-SENSITIVE PROSTATE CANCER.PFIZER INC - PHASE 3 ARCHES TRIAL MET ITS PRIMARY ENDPOINT.PFIZER INC - PRELIMINARY SAFETY ANALYSIS OF ARCHES TRIAL APPEARS CONSISTENT WITH SAFETY PROFILE OF XTANDI IN PREVIOUS CLINICAL TRIALS.PFIZER - RESULTS FROM ARCHES DEMONSTRATE STATISTICALLY SIGNIFICANT IMPROVEMENT IN MARKER OF DISEASE PROGRESSION, RADIOGRAPHIC PROGRESSION-FREE SURVIVAL.  Full Article

Astellas Pharma Inc Says FDA Approves Xospata, Marking U.S. Entry Into Blood Cancer Treatment
Wednesday, 28 Nov 2018 

Nov 29 (Reuters) - Astellas Pharma Inc <4503.T>::U.S. FDA APPROVES XOSPATA FOR ADULT PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA WITH FLT3 MUTATION.XOSPATA IS ONLY FLT3 INHIBITOR APPROVED BY FDA FOR PATIENTS WITH RELAPSED OR REFRACTORY AML WITH FLT3 MUTATION.XOSPATA APPROVAL MARKS ASTELLAS'S U.S. ENTRY INTO TREATMENT OF BLOOD CANCERS.  Full Article

FDA Approves Astellas Pharma's Xospata Tablets
Wednesday, 28 Nov 2018 

Nov 28 (Reuters) - U.S. Food and Drug Administration::FDA APPROVES ASTELLAS PHARMA'S XOSPATA (GILTERITINIB) TABLETS, FOR ORAL USE.FDA - XOSPATA INDICATED FOR TREATING ADULT PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA WITH A FLT3 MUTATION AS DETECTED BY FDA-APPROVED TEST.  Full Article

Astellas Submits New Drug Application In Japan Of Roxadustat For Treatment Of Anemia Associated With Chronic Kidney Disease In Patients On Dialysis
Monday, 1 Oct 2018 

Oct 1 (Reuters) - FibroGen Inc ::ASTELLAS SUBMITS NEW DRUG APPLICATION IN JAPAN OF ROXADUSTAT FOR THE TREATMENT OF ANEMIA ASSOCIATED WITH CHRONIC KIDNEY DISEASE IN PATIENTS ON DIALYSIS.FIBROGEN INC - ANNOUNCED ASTELLAS SUBMITTED A NEW DRUG APPLICATION (NDA) FOR MARKETING APPROVAL IN JAPAN OF ROXADUSTAT.  Full Article

Astellas Pharma says blincyto® for drip infusion 35 μg approved in Japan for treatment of relapsed or refractory b-cell acute lymphoblastic leukemia
Tuesday, 25 Sep 2018 

Sept 25 (Reuters) - Astellas Pharma Inc <4503.T>:Amgen Astellas BioPharma K.K. and Astellas Pharma Inc. today announced that Ministry of Health, Labour and Welfare has granted marketing approval for antineoplastic drug/bispecific antibody product.BLINCYTO® Drip Infusion 35 μg for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia (ALL).  Full Article

Astellas Pharma announces approval in Japan for XOSPATA® 40 mg Tablets for treatment of FLT3mut+ relapsed or refractory AML
Friday, 21 Sep 2018 

Sept 21(Reuters) - Astellas Pharma Inc <4503.T>:Says it announced that XOSPATA® Tablets 40 mg, a FLT3 (FMS-like tyrosine kinase 3) inhibitor received manufacturing and marketing approval for the treatment of FLT3 mutation-positive relapsed or refractory acute myeloid leukemia (AML) in Japan.  Full Article

Aquinox Pharmaceuticals Received Notice Terminating License Agreement That Had Been Entered Between Co's Unit And Astellas US LLC
Friday, 7 Sep 2018 

Sept 7 (Reuters) - Astellas Pharma Inc <4503.T>::AQUINOX PHARMACEUTICALS - ON SEPT 4, RECEIVED NOTICE TERMINATING LICENSE AGREEMENT THAT HAD BEEN ENTERED BETWEEN CO'S UNIT AND ASTELLAS US LLC.AQUINOX PHARMACEUTICALS INC - TERMINATION OF THE ASTELLAS AGREEMENT WILL BE EFFECTIVE MARCH 4, 2019- SEC FILING.  Full Article

Astellas Pharma Considering Sale Of Some Central And Eastern European Assets- Bloomberg
Wednesday, 18 Jul 2018 

July 18 (Reuters) - :ASTELLAS PHARMA IS CONSIDERING A SALE OF SOME CENTRAL AND EASTERN EUROPEAN ASSETS- BLOOMBERG,CITING SOURCES.  Full Article

FDA Approves XTANDI For Treating Men With Non-Metastatic Castration-Resistant Prostate Cancer
Friday, 13 Jul 2018 

July 13 (Reuters) - Astellas Pharma Inc <4503.T>::U.S. FDA APPROVES XTANDI® (ENZALUTAMIDE) FOR THE TREATMENT OF MEN WITH NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC).U.S. FDA APPROVES XTANDI® (ENZALUTAMIDE) FOR THE TREATMENT OF MEN WITH NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC).ASTELLAS PHARMA - U.S. FDA APPROVES XTANDI FOR TREATING MEN WITH NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER BASED ON RESULTS FROM PHASE 3 PROSPER TRIAL.  Full Article

Photo

Cash-hoarding Japanese firms please investors as share buybacks hit record

TOKYO/HONG KONG Japanese share buybacks have hit a record this fiscal year and are set to maintain the booming growth as cash-rich companies bow to pressure from investors and the government to boost returns and improve governance.